New hope for haemophilia a patients: immune tolerance induction may eliminate clotting factor blockers

NCT ID NCT02207894

Recruiting now Disease control Sponsor: Haemophilia Centre Rhine Main Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether a treatment called immune tolerance induction (ITI) can help people with haemophilia A who have developed inhibitors—antibodies that block standard clotting factor therapy. Researchers will give high doses of individualized factor VIII concentrates to 300 male patients of any age. The goal is to see if ITI can lower inhibitor levels and restore normal clotting factor activity, reducing bleeding episodes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Factor VIII concentrates (individualized selection) and high-dose immune tolerance induction (ITI)
What this could lead to: If successful, this could help haemophilia A patients with inhibitors regain effective clotting factor treatment, reducing bleeding risks.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. ITI can be lengthy and may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAEMOPHILIA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HAEMOPHILIA A

Contacts and locations

Locations

Haemophilia Centre Rhine Main
RECRUITING

Frankfurt am Main, Hesse, 60596, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.